Results 41 to 50 of about 8,062 (139)

Using high‐resolution array tomography to validate the use of synaptic vesicle glycoprotein 2A as a biomarker for synaptic loss in Alzheimer's disease [PDF]

Alzheimers Dement
Abstract Background Numerous studies have used Synaptic Vesicle Glycoprotein 2A (SV2A) as a radioligand target during in‐vivo Positron Emission Tomography (PET) in humans to investigate the synaptic loss that strongly correlates with cognitive decline in Alzheimer's disease (AD).
Young L, King D, Chang Y, Holt K, Gladstein S, Finnema S, Spires‐Jones T.   +6 more
europepmc   +3 more sources

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Alzheimer’s Research & Therapy, 2020
Background Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD ...
Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo, Susan M. Catalano, the Synaptic Health Endpoints Working Group   +15 more
doaj   +1 more source

Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study

NeuroImage, 2021
Rationale: 11C-UCB-J binds to synaptic vesicle glycoprotein 2A, a protein ubiquitously expressed in presynaptic nerve terminals, and can therefore serve as in vivo proxy of synaptic density.
Laura Michiels, Aline Delva, June van Aalst, Jenny Ceccarini, Wim Vandenberghe, Mathieu Vandenbulcke, Michel Koole, Robin Lemmens, Koen Van Laere   +8 more
doaj   +1 more source

Exploring Synaptic Vesicle Glycoprotein 2A (SV2A) Alterations in Alzheimer's Disease Using Targeted Mass Spectrometry [PDF]

Alzheimers Dement
Abstract Background SV2A levels are decreased in Alzheimer's disease (AD) brains, as revealed by Positron Emission Tomography (PET). Whether this decrease is due to synapse loss or SV2A protein loss remains unclear, hindering treatment development and interpretation of SV2A PET as a biomarker ...
Zetterberg H.
europepmc   +2 more sources

Generation of a SV2A knockout human embryonic stem cell line by CRISPR/Cas9 system

Stem Cell Research
Synaptic Vesicle Glycoprotein 2A (SV2A) is a ubiquitously expressed brain glycoprotein, localized to synaptic terminals. It regulates vesicle exocytosis, maintains neurotransmitter release, and serves as a receptor for both botulinum neurotoxins (e.g ...
Feng Yao, Xing Qi, Shan Yongli, Zhong Xiaofen   +3 more
doaj   +1 more source

Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery

Frontiers in Molecular Neuroscience, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Yifan Zhang, Lise Heylen, Michèle Partoens, James D. Mills, James D. Mills, James D. Mills, Rafal M. Kaminski, Rafal M. Kaminski, Patrice Godard, Michel Gillard, Peter A. M. de Witte, Aleksandra Siekierska   +11 more
doaj   +1 more source

SV2A PET imaging in human neurodegenerative diseases

Frontiers in Aging Neuroscience
This manuscript presents a thorough review of synaptic vesicle glycoprotein 2A (SV2A) as a biomarker for synaptic integrity using Positron Emission Tomography (PET) in neurodegenerative diseases.
Mahsa Shanaki Bavarsad, Lea T. Grinberg
doaj   +1 more source

Overnight switch from levetiracetam to brivaracetam. Safety and tolerability

Epilepsy & Behavior Reports, 2021
Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess
L. Abraira, J. Salas-Puig, M. Quintana, I.M. Seijo-Raposo, E. Santamarina, E. Fonseca, M. Toledo   +6 more
doaj   +1 more source

Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity

Advanced Science, EarlyView.
This study identifies synapse‐enriched deubiquitinase UCHL1 as an early Aβ‐responsive regulator of retinal synaptopathy in Alzheimer's disease. Retinal UCHL1 loss accompanies excitatory synapse degeneration, p75NTR activation, and neuroinflammation, and predicts Braak stage and cognitive decline. Aβ42 fibrils trigger synaptic and UCHL1 depletion before
Altan Rentsendorj, Jean‐Philippe Vit, Alexandre Hutton, Yosef Koronyo, Saba Shahin, Edward Robinson, Ernesto Barron, Anthony Rodriguez, Ousman Jallow, Julia Sheyn, Bhakta Prasad Gaire, Lalita Subedi, Miyah R. Davis, Barathan Gnanabharathi, Alexander V. Ljubimov, Stuart L. Graham, Vivek K. Gupta, Mehdi Mirzaei, Debra Hawes, Katlin Silm, Keith L. Black, Lon S. Schneider, Alfredo A. Sadun, Jesse G. Meyer, Dieu‐Trang Fuchs, Maya Koronyo‐Hamaoui   +25 more
wiley   +1 more source

Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease

NeuroImage, 2021
Purpose: 11C-UCB-J PET imaging, targeting synaptic vesicle glycoprotein 2A (SV2A), has been shown to be a useful indicator of synaptic density in Alzheimer's disease (AD).
Yihuan Lu, Takuya Toyonaga, Mika Naganawa, Jean-Dominique Gallezot, Ming-Kai Chen, Adam P. Mecca, Christopher H. van Dyck, Richard E. Carson   +7 more
doaj   +1 more source